LivaNova completes initial closing of heart valve business sale to Gyrus Capital

LivaNova completed the initial closing of the divestiture of its heart valve business to Gyrus Capital for €60 million ($73 million). The business will be managed by Corcym, which acquired the Saluggia and Vancouver manufacturing facilities.

“LivaNova announced June 1 it successfully completed the initial closing of the divestiture of its heart valve business to the investment firm Gyrus Capital for €60 million ($73 million).”dicardiology.com

• 1 source
• dicardiology.comLivaNova Sells Heart Valve Business to Gyrus Capital | DAICJun 2, 2021

Summarized from public sources; check the original articles before acting on it.